Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × plerixafor × Lymphoid × Clear all

Phase

Phase 2 25 Phase 1 5 Phase NA 3 Phase 1/2 3 Phase 3 2 Phase 4 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Cyclophosphamide 21 Vincristine 19 Methotrexate 19 Rituximab 18 Dexamethasone 17 Cytarabine 17 Mercaptopurine 15 Doxorubicin 11 Daunorubicin 10 Asparaginase 10 Prednisolone 8 Granulocyte Colony-Stimulating Factor 8 fludarabine 7 Prednisone 7 Etoposide 7 Thioguanine 6 Teniposide 6 Ifosfamide 6 Idarubicin 6 pegylated granulocyte colony-stimulating factor 4 Vindesine 4 Stem Cell Transplantation 4 Aprepitant 4 zanubrutinib 3 pegfilgrastim 3 fludarabine phosphate 3 entecavir 3 denileukin diftitox 3 VAP-cyclo protocol 3 Ketamine 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05510544 2023-03-13

Plerixafor for Poorly Mobilized Lymphoma

Peking University

Phase 4 Unknown

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡